Description
-
Alpha-Fetoprotein (AFP)
Diagnosing of cancers(liver, testicles, ovaries) & monitoring therapeutic effect
High levels of AFP in adults may indicate the possibility of the liver, the ovaries, or the testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. The AFP plus measures the level of AFP to help diagnose or rule out related abnormalities.
- Diagnosis diseases
- Liver cancer, Viral hepatitis, Ovarian cancer, testicular cancer
Available Instruments
About Using Reagent
-
Sample Types
whole blood, plasma, serum
-
Reaction Time
15 mins
-
Detection Range
AFIAS (5 – 350 ng/ml)
ichroma™ (5 – 350 ng/ml) -
Indication
Liver cancer, Viral hepatitis, Ovarian cancer, Testicular cancer
-
CA125
A useful cancer biomarker that aids in the diagnosis of ovarian cancer.
A useful cancer biomarker that aids in the diagnosis of ovarian cancer.
The CA125 test measures the amount of CA125 in the blood, which can assist in diagnosing ovarian cancer.
- Diagnosis diseases
- Ovarian cancer
Available Instruments
About Using Reagent
-
Sample Types
Serum, Plasma
-
Reaction Time
12 mins
-
Detection Range
5-700 U/mL
-
Indication
Ovarian cancer
-
CA19-9
Supporting to diagnose pancreatic cancer
CA19-9 is the common term for carbohydrate antigen sialyl Lewis a and it is also called cancer antigen 19-9. It is a protein that exists on the surface of certain cancer cells, and normal results are less than 37 U/mL. A high amount of CA 19-9 is most often caused by pancreatic cancer, but it can be elevated in many other cancers and other diseases and it is not useful for people who are Lewis antigen-negative.
- Diagnosis diseases
- Pancreatic Cancer
Available Instruments
About Using Reagent
-
Sample Types
Serum, Plasma
-
Reaction Time
12 mins
-
Detection Range
8-1000 U/mL
-
Intended Use
Quantitative determination of CA19-9 in human serum/plasma
-
Carcinoembryonic antigen (CEA)
Carcinoembryonic antigen (CEA)
Measuring the activity of the carcinoma in the body
A high level of CEA in adults can be a sign of certain types of cancers in organs like the colon and rectum, prostate, ovary, lung, thyroid, or liver. The CEA test measures the level of CEA in the patient blood including treatment response and recurrence of cancer patients.
Available Instruments
About Using Reagent
-
Sample Types
plasma, serum
-
Reaction Time
12 mins
-
Detection Range
AFIAS (1 – 500 ng/ml)
ichroma™ (1 – 500 ng/ml) -
Indication
Colorectal cancer, Lung cancer. Rectal cancer, Pancreatitis
-
-
Cyfra21-1
Supporting to diagnose Non-Small-Cell Lung Cancer (NSCLC)
Cyfra21-1 belongs to a cytokeratin family, which is normally expressed in epithelial tissues and forms the epithelial cells’ filament cytoskeleton and it can be used as a circulating tumor marker. Although expressed in all body tissues, its major occurrence is in the lung, particularly in lung cancer tissues, so it is a sensitive, specific, and valuable biomarker for estimation of diagnosis, prognosis, and therapy monitoring of non-small-cell lung cancer (NSCLC), especially of squamous cell subtype.
- Diagnosis diseases
- Lung Cancer
Available Instruments
About Using Reagent
-
Sample Types
Serum, Plasma
-
Reaction Time
12 mins
-
Detection Range
1-500 ng/mL
-
Intended Use
Quantitative determination of Cyfra21-1
-
Fecal Occult Blood (iFOB) Neo
Detecting hemoglobin in fecal occult blood
The existence of hemoglobin in stools indicates possible polyps, hemorrhoids, ulcers, and others as well as the colorectal cancer. The iFOB Neo test detects the miniscule amount of blood in the stools. Detection of hemoglobin should warrant further examination.
- Diagnosis diseases
- Colorectal cancer, Hemorrhoids, Polyps, Colitis
-
Free PSA
Screening for the prostate cancer, monitoring treatment effectiveness, assess risk & detect recurrence
Free PSA measure the amount of PSA that is not bound to proteins in the blood, helping to diagnose prostate cancer and contributing to the staging of cancer and monitoring of cancer treatment, including treatment response and recurrence in cancer patients.
- Diagnosis diseases
- Prostate Cancer, Prostatitis, Benign Prostatic Hyperplasia (BPH)
Available Instruments
About Using Reagent
-
Sample Types
Whole Blood, Serum, Plasma
-
Reaction Time
12 mins
-
Detection Range
0.05-50 ng/mL
-
Indication
Prostate cancer, prostatitis, benign prostatic hyperplasia (BPH)
-
Prostate Specific Antigen (PSA)
Screening for the prostate cancer & monitoring the effects of the treatment
This test helps in the early detection of prostate diseases such as enlarged prostate and prostatitis and prostate cancer by quantifying PSA in male blood, as well as observation of treatment effects and monitoring of recurrence.
- Diagnosis diseases
- Prostate Cancer, Prostatitis, benign prostatic hyperplasia (BPH)
Available Instruments
About Using Reagent
-
Sample Types
whole blood, plasma, serum
-
Reaction Time
15 mins
-
Detection Range
AFIAS (0.5 – 100 ng/ml)
ichroma™ ( S/P : 0.1 – 100 ng/ml) ( WB : 0.5 – 100 ng/ml) -
Indication
Prostatitis, benign prostatic hyperplasia (BPH), Prostate Cancer
Reviews
There are no reviews yet.